Jorge Osvaldo

I, Jorge Osvaldo Cáneva, nominated by Argentina and residing in Argentina, Member of the Medical and Chemicals Technical Options Committee declare as follows:

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am Chief of the Pulmonary Section at the University Hospital of the Favaloro Foundation, Buenos Aires, Argentina. Besides, I belong as Member of the Pulmonary Hypertension Group and the Intrathoracic Transplantation Group of the same institution. My responsibilities include medical assistance of patients with moderate and severe respiratory and cardiopulmonary diseases referred to this institution, teaching at the University Medical School of the Favaloro Foundation and research in pulmonary vascular diseases, chronic airway diseases and lung transplantation.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service.
4. My interests, and those of my personal partner and dependents, include the following

1. Proprietary interests: I do not have proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces).
2. Financial interests: I do not own stock in companies producing ODS or alternatives or substitutes to ODS, and do not have an interest in the outcome of essential use nominations.
3. Employment, consultancy, directorship or other positions:  I have interest in the topics of the Montreal Protocol based on the fact that I take care of patients with severe respiratory and cardiorespiratory diseases in the main institution dedicated to intrathoracic transplantation in Argentina, patients that usually are treated with all inhaled therapies commercially available. I am the Chief of the Pulmonary Section at the University Hospital of the Favaloro Foundation (www.fundacionfavaloro.org; BuenosAires, Argentina) since 2000, and Professor of Internal Medicine of the University Medical School at the same institution. I have been nominated as Professor of the International Master in Pulmonary Hypertension sponsored by the Spanish Society of Cardiology for the period 2014-2016 and 2016-2018. Furthermore, he has been Chairman of the VIII Latin American Symposium in Pulmonary Hypertension that took place in Sao Paulo, Brazil, July 2016, sponsored  by Bayer. Currently I state as Ex-President of the Argentine Association of  Respiratory Medicine (Asociación Argentina de Medicina Respiratoria; AAMR; www.aamr.org.ar), main association in Pulmonary Medicine in Argentina, and was Member of the Scientific Committee of the 2015 Annual Meeting of this society.  I serve as member of the Editorial Board of the European Respiratory Society (ERS) since 2013. I was Governor of the American College of Chest Physician (ACCP; www.chestnet.org) in Argentina between the period 2006-2009. I am the Coordinator of the Bi-National Programme for Pulmonary and Cardiopulmonary Transplantation between Argentina and Uruguay, since 2003. I have been involved in severe respiratory diseases, pulmonary vascular diseases and lung transplantation programmes. I do not own stock in companies producing ODS or alternatives or substitutes to ODS; I do not consult for organizations seeking to phase out ODS. My spouse, has no relationship with any pharmaceutical company. Neither my spouse nor I, do not receive any honorarium or grant from the government, national or international non-for-profit organization.
4. Government advice and other policy development: I do not provide any government advice.
5. Paid research activities, fellowships or grants: During 2003 and 2004, I was involved in consultation for AstraZeneca Argentina about dry powder inhalers (DPI). Between 1993 and 2008, I have served as independent consultant on long-term oxygen therapy for Air Liquide Argentina. I am Principal Investigator (PI) of the following randomized clinical trials (RCTs) in patients suffering from pulmonary hypertension: SERAPHIN 303-OL and GRIPHON 303-OL (sponsored by Actelion Pharmaceuticals, Switzerland), CATALYST (sponsored by Reata Pharmaceuticals, USA), EXPERT (sponsored by Bayer, Germany) and PERFORMA (sponsored by Bagó, Argentina).
6. Other interests: None.

5. The source of funding for my participation in the work of the Medical and Chemicals Technical Options Committeeis: UNEP’s Ozone Secretariat has paid travel to MCTOC meetings.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have declined to disclose information falling within paragraph 10 of those Guidelines and I undertake to ensure that I am completely excluded from discussion and decisions on topics related to the information that I have declined to disclose. 
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
9. I understand that this DOI will expire no later than one year after I have signed it.

Name: Jorge Osvaldo Cáneva

Date: 5th February 2018